The use of concomitant medications for Crohn’s disease was similar between the treatment groups, with 30% of patients using corticosteroids at baseline and 50% of patients using concomitant immunomodulators, including 24% of patients using concomitant anti-TNF agents. Here, TNF is linked to Crohn disease.